SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-015494
Filing Date
2023-05-04
Accepted
2023-05-04 09:05:32
Documents
14
Period of Report
2023-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20230504.htm   iXBRL 8-K 38711
2 EX-99.1 a991pressreleasedatedmay42.htm EX-99.1 98171
6 x4logo.jpg GRAPHIC 4345
  Complete submission text file 0001628280-23-015494.txt   298856

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20230504.xsd EX-101.SCH 1902
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20230504_lab.xml EX-101.LAB 25848
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20230504_pre.xml EX-101.PRE 13581
8 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20230504_htm.xml XML 11454
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 23886795
SIC: 2836 Biological Products, (No Diagnostic Substances)